DRLALPATHLABS / Q4-FY26 / claim-ledger

Audit the questions that mattered.

Dr Lal Path · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY26 · 2026-05-13Back to quarter ↗

Questions audited

12

Answered directly

58%

Numeric claims

5

Consistency

contradicted

Question ledger

What was answered, and how?

Toss · BNP Pariba

partial

Business mix and rationale for acquiring Shabaskar in Mumbai.

the reason we have acquired this asset is this uh is a quite an old operating lab it has got a legacy of over 45 years in that geography and uh you know it's in a micro market in Mumbai where we actually with uh either Lalab or suburban don't really have a significant presence

Toss · BNP Pariba

evasive

Margin profile of the acquired asset.

we have not disclosed the Aida margin uh uh uh for as of now. So uh we have disclosed this uh it's about a 6 cr kind of turnover topline. It's a small asset.

Toss · BNP Pariba

direct

Volume growth this quarter and outlook.

this quarter uh volume growth has come at 8.2%. But uh you know even in the last quarter I had mentioned that uh you know quarter to quarter even on volume is is not really u a very uh robust way to look at it.

Air Chalk · JM Financial

direct

Reason for sharp jump in other expenses and margin outlook.

we have spent a little bit extra uh as we said uh we are investing in the business uh we have spent extra amount on our infra uplifting of infra including Delhi and NCR as well. Second is uh we we are spending uh more amount on&p

Air Chalk · JM Financial

evasive

Price hike possibility and margin improvement.

the price hike we have we have said that you know we have completed three years since we took our last price increase. uh but we also said that you know um we will kind of wait and watch

Anchul Aaral · MK

direct

Confirmation of FY27 revenue guidance.

Yeah, early to mid- teens.

Anchul Aaral · MK

partial

Sustainability of volume growth and contributing geographies.

I would not uh kind of correlate it to a quarter alone because again if I am I'm talking about let's say if you look at the annual trajectory and that's a much better way to judge

Anchul Aaral · MK

direct

Capex guidance for FY27 and B2C revenue share.

for capex I think uh we are planning to be in the range of 100 to 120 cr uh kind of capex for the next year the B2C contribution this year is about 75%.

Abdul Kadir Puranwalla · ICICI securities

partial

Structural tailwinds for FY27 growth and tier 3/4 geography contribution.

the confidence behind the early to mid- teens is is driven by the work which has been happening in the last uh you know 2 years. I think the the continuous uh you know expansion of of lab infrastructure and the collection network

Binoiparumpil · Ara Capital

direct

Impact of Middle East war on raw material costs.

as of now uh no uh because we we are uh you know obviously we have ample sufficient inventory for the next 3 4 months and we have long-term contracts as well.

Rajat Balva · Kizuna wealth

partial

Competition intensity in Mumbai and future bolt-on acquisitions.

within Mumbai there is a micro market uh where you know uh we don't have a presence either through the suburban brand or through Lalpath labs. So this acquisition kind of fills that gap for us

Rishiesh Tulle · Tokai Investors

evasive

Prioritization of investments in labs vs collection centers and ROI thresholds.

there are new uh satellite labs that we are going to open up right then then there is uh you know maybe a few uh high-end radiology uh setups that we will we will uh we will do plus we have acquired a uh uh you know an asset to set up a precision diagnostic lab